August 17, 2014 | An Israeli company developing foam-based drugs for skin diseases, Foamix, has published a draft prospectus for raising up to $75 million on Wall Street. The company is set to be valued at $100-$200 million, after money with investment banks Oppenheimer and Maxim leading the offering. Foamix was founded in 2003 by CEO Dov Tamarkin and chairman and COO Meir Eini, both of whom where previously the founders of medical equipment companies.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments